MedTrace Logo

A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence

NCT05674045 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2023-01-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether EG017 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.

Conditions

  • Stress Urinary Incontinence

Interventions

DRUG

EG017 3mg

EG017 3mg/day Oral administration for 12 weeks, once daily

DRUG

EG017 6mg

EG017 6mg/day Oral administration for 12 weeks, once daily

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-06
Primary Completion
2022-01-06
Completion
2022-09-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05674045 on ClinicalTrials.gov